ArticleUrologia internationalis2026
12-Years Real-Life Data on Successful Management of Recurrent Urinary Tract Infections by OM-89 and Its Impact on Bacterial Resistance.
Article in Urologia internationalis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEvaluate long-term effectiveness, safety and tolerability of OM-89 (Uro-Vaxom®), an oral immunomodulator derived from bacterial lysates of Escherichia coli, in the prophylactic management of recurrent urinary tract infections (rUTIs) in women in a real-world outpatient gynecology setting.
methodsRetrospective, single center observational study based on data from women with a diagnosis of rUTI who received OM-89 as a single 90-day cycle or two or more cycles. Data were collected from medical records at the Mexican Institute for Infectious Diseases in Obstetrics and Gynecology (IMIGO) clinic in Monterrey, Mexico, between January 2023 and March 2024. Primary outcome was the time free of UTI recurrence. Secondary outcomes were the risk factor profiles in the treated groups, urine and vaginal antibiotic resistance profiles and the incidence of adverse events.
resultsA total of 208 women with rUTI were included. 72.1% received a single OM-89 90-day cycle, while 27.9% underwent two or more 90-day cycles. The mean recurrence-free interval after one OM-89 cycle was 5.3 ± 2.6 years and 4.6 ± 2.5 years for those with OM-89 multiple cycles. Post-treatment bacterial cultures showed a significant reduction in bacterial resistance in 72.4% of urine samples and in 37.0% of vaginal samples (p < 0.001).
conclusionA single 90-day course of OM-89 was associated with a long-term reduction in UTI recurrences and antibiotic resistance in women with rUTIs. These findings support its use as a safe and effective nonantibiotic preventive strategy in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.